# NeoRank: Accessible Neoantigen Immunogenicity Prediction

[![License: MIT](https://img.shields.io/badge/License-MIT-yellow.svg)](https://opensource.org/licenses/MIT)
[![Python 3.8+](https://img.shields.io/badge/python-3.8+-blue.svg)](https://www.python.org/downloads/)
[![DOI](https://img.shields.io/badge/DOI-10.xxxx%2Fxxxxxx-blue)](https://doi.org/placeholder)

> **Making cancer immunotherapy research accessible worldwide with a $300 solution**

NeoRank is a machine learning pipeline that predicts neoantigen immunogenicity using only peptide sequences and HLA typingâ€”achieving clinical-grade performance (AUROC: 0.824 Â± 0.018) at ~10% of the cost of current multi-omics tools.

## ğŸ¯ Key Features

- **Minimal Input Requirements**: Only peptide sequences and HLA typing needed
- **Clinical-Grade Performance**: AUROC 0.824, competitive with tools requiring expensive WES/RNA-seq
- **Cost-Effective**: ~$300 per patient vs $1,000-$5,000 for multi-omics approaches
- **Fast Processing**: 2-3 days vs 2-6 weeks for traditional pipelines
- **Accessible Infrastructure**: Works with basic lab equipment (~$100K vs $1.5M+ sequencers)
- **Universal Applicability**: Validated across cancer, TB, HIV, and COVID-19 datasets

## ğŸ“Š Performance Metrics

| Metric | Score | Std Dev |
|--------|-------|---------|
| AUROC | 0.824 | Â± 0.018 |
| AUPRC | 0.XXX | Â± 0.XXX |
| F1-Score | 0.XXX | Â± 0.XXX |
| Brier Score | 0.XXX | Â± 0.XXX |

*10-fold stratified cross-validation on 6,757 epitopes from IEDB*

## ğŸš€ Quick Start

### Installation

```bash
# Clone repository
git clone https://github.com/yourusername/NeoRank.git
cd NeoRank

# Create conda environment
conda env create -f environment.yml
conda activate neorank

# Install NetMHCpan 4.2 (see tools/netmhcpan_setup.md)
```

### Basic Usage

```python
from neorank import NeoRankPredictor

# Initialize predictor
predictor = NeoRankPredictor(model_path='models/neorank_model.pkl')

# Predict immunogenicity
peptides = ['SIINFEKL', 'KVAELVHFL']
hla_types = ['HLA-A*02:01', 'HLA-A*02:01']

results = predictor.predict(peptides, hla_types)
print(results)
```

### Training Your Own Model

```bash
# Download IEDB data (see data/raw/download_instructions.md)
python scripts/train_model.py --config configs/default_config.yaml
```

## ğŸ“š Documentation

- [Installation Guide](docs/installation.md)
- [Usage Guide](docs/usage_guide.md)
- [Feature Documentation](docs/feature_documentation.md)
- [API Reference](docs/api_reference.md)
- [FAQ](docs/FAQ.md)

## ğŸ”¬ Scientific Background

### The Problem

- 70% of cancer deaths occur at late stages where tumors resist treatment
- Current neoantigen selection tools require expensive multi-omics data
- Only ~5% of global labs have access to required infrastructure ($500K-$1.5M sequencers)

### The Solution

NeoRank demonstrates that **peptide features and HLA typing alone are sufficient** for accurate neoantigen prediction by:

1. **Mutation Features (55% of predictive power)**
   - Peptide length, amino acid composition
   - Hydrophobicity, charge, aromatic content
   - Polarity and structural properties

2. **Binding Features (45% of predictive power)**
   - NetMHCpan-predicted HLA binding affinity
   - Anchor residue analysis (P2, P9)
   - Strong/weak binder classification

### Real-World Impact

- Enables 50% of global labs (vs current 5%) to conduct neoantigen research
- Opens access to millions of peptide/HLA datasets
- Accelerates development of personalized cancer vaccines

## ğŸ† Benchmarking

NeoRank performance compared to existing tools:

| Tool | AUROC | Inputs Required | Cost per Patient |
|------|-------|----------------|------------------|
| NeoRank | 0.824 | Peptide + HLA | ~$300 |
| NeoDisc | 0.83 | WES + RNA-seq | ~$2,500 |
| NeoTImmuML | 0.82 | WES + RNA-seq + VAF | ~$3,500 |
| imNEO | 0.84 | Full multi-omics | ~$5,000 |
| NetMHCpan (baseline) | 0.65 | Peptide + HLA | ~$300 |

## ğŸ“– Citation

If you use NeoRank in your research, please cite:

```bibtex
@software{ma2025neorank,
  author = {Ma, Eddy},
  title = {NeoRank: Accessible Neoantigen Immunogenicity Prediction},
  year = {2025},
  institution = {Raleigh Charter High School},
  url = {https://github.com/yourusername/NeoRank}
}
```

## ğŸ“„ License

This project is licensed under the MIT License - see the [LICENSE](LICENSE) file for details.

## ğŸ™ Acknowledgments

- **Data Source**: [Immune Epitope Database (IEDB)](https://www.iedb.org)
- **Binding Predictions**: [NetMHCpan 4.2](https://services.healthtech.dtu.dk/services/NetMHCpan-4.1/)
- **Inspiration**: Research teams advancing personalized cancer immunotherapy

## ğŸ“§ Contact

**Eddy Ma**  
Raleigh Charter High School  
Cary, North Carolina, USA  
Email: [your-email@example.com]

## ğŸ¤ Contributing

Contributions are welcome! Please see [CONTRIBUTING.md](CONTRIBUTING.md) for guidelines.

## ğŸ—ºï¸ Roadmap

- [ ] MHC Class II support (CD4+ T cells)
- [ ] Expanded HLA allele coverage
- [ ] Web-based interface
- [ ] Integration with clinical pipelines
- [ ] Multi-species support

---

**Made with â¤ï¸ for accessible cancer research**
